Almirall
 |
|
Solutions with you in mind
|
|
| Sociedad Anónima (Mercado Continuo: ALM-MC: ALM) | |
| Founded | 1943 |
| Founder | Antonio Gallardo Carreras |
| Headquarters | Ronda del General Mitre, 151 08022 Barcelona Spain |
|
Area served
|
International |
| Products | Ebastel, Monodox, Acticlate, Almogran, Tesavel & Efficib, Solaraze, Airtal, Decoderm, Cordran, Almax, Parapres, Balneum, Sativex, Cleboril, Monovo, Actikerall. |
| Revenue | €769 million (2015) |
|
Number of employees
|
1,788(2016) |
| Website | www.almirall.com |
Almirall, S.A. (Ticker Bolsa de Madrid: ALM) is a pharmaceutical company, with headquarters in Barcelona, founded in 1943.
In 2015, it generated total revenue of 769 million € and became the leading pharmaceutical company in R&D investment in Spain.
With over 1,788 employees (2015), it has a presence, through its 13 affiliates in Europe and United States.
1943 Foundation of Laboratorios Almirall SA.
1979 Launch of the gastroprokinetic clebopride in Spain, the first product from the company’s internal research to obtain a license in another country.
1984 Launch of the antacid almagate in Spain.
1985 Launch of the local anti-inflammatory piketoprofen in Spain.
1990 Launch of the antihistamine ebastine and the gastroprokinetic cinitapride in Spain. Opening of the affiliate in Belgium.
1992 Launch of the anti-inflammatory aceclofenac in Spain.
1993 Opening of the affiliate in Portugal.
1994 Opening of the new headquarters of Almirall in Barcelona.
1995 Inauguration of the extension and remodelling of the pharmaceutical plant in Sant Andreu de la Barca (Barcelona).
1997 Merger of Almirall and Prodesfarma.
2000 Approval of the marketing of the anti-migraine agent almotriptan by the FDA. This is the first medicine with Spanish R&D to receive approval by the FDA.
...
Wikipedia